CD8A and neoplasm: Evaluation of viable tumor presence through BLI did not show any statistically significant changes across treatment groups at the initial [89Zr]-CD8 ImmunoPET imaging timepoint (D30) or one week following immunotherapy (p > 0.05), see Figures 3C. Response classification through BLI, defined as less than 20% increase in tumor burden over the course of evaluation, revealed an absence of responders in the control group (N = 0/7), while immunotherapy treated mice had a 42.9% response rate in all groups (N = 3/7 for anti-PD1, M002 and combination), as shown in Figure 4A.